Senhwa Biosciences, Inc. (TPEX:6492)

Market Cap	3.93B +25.5%
Revenue (ttm)	1.06M +6.0%
Net Income	-270.27M
EPS	-3.03
Shares Out	89.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,157
Open	44.60
Previous Close	44.45
Day's Range	43.75 - 44.60
52-Week Range	32.00 - 66.50
Beta	0.88
Analysts	Buy
Price Target	84.00 (+90.91%)
Earnings Date	Aug 11, 2026

About Senhwa Biosciences

Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. It also provides technical a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6492

Financial Performance

In 2025, Senhwa Biosciences's revenue was 1.07 million, an increase of 7.00% compared to the previous year's 1.00 million. Losses were -264.77 million, -9.86% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error